Con: The treatment of the granulomatous response is beneficial in acute sarcoidosis  by Reich, Jerome M.
Respiratory Medicine (2010) 104, 1778e1781ava i lab le at www.sc iencedi rect .com
journal homepage : www.e lsev ie r . com/ loca te / rmedCon: The treatment of the granulomatous response
is beneficial in acute sarcoidosis*Jerome M. Reich*Earl A Chiles Research Institute, Portland Providence Medical Center, Bldg A, 4805 NE Glisan St., Portland, OR 97213, USA
Received 6 July 2010
Available online 12 October 2010Human experience, which is constantly contradicting
theory, is the great test of truth
Samuel Johnson
Introduction
Sarcoidosis is viewed as a genetically conditioned disease
defined by a systemic, noncaseating granulomatous response
(SGR) to an unknown antigenic stimulus, with a 1e5% range in
(cumulative) mortality due largely to pulmonary fibrosis and
cor pulmonale.1 Absent compelling indications such as
hypercalcemia or cardiac involvement, the decision to inter-
vene with corticosteroid therapy (CST) typically arises within
thefirst two years out of concern that this outcomemayensue
in persons with unresolving pulmonary shadowing.
Izumi, in a seminal case-control study of largely
asymptomatic, predominantly stage I sarcoidosis, observed
a marked adverse effect of elective CST.2 Gottlieb et al.3
observed that the relapse rate requiring retreatment in
persons initially receiving CST for compelling symptoms was
9-fold the rate (74% vs.8%) in persons whose symptoms were
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doi:10.1016/j.rmed.2010.07.002The striking difference in relapse rate between treated
and untreated patients suggests that patients with
disease that would later be severe and protracted were
almost unerringly identified early in their course. One
explanation is that severe presenting symptoms portend
a protracted and recurrent course; an alternative
explanation is that corticosteroids contributed to the
prolongation of the disease by delaying resolution.
This opposing view summarizes evidence that elective
CST is harmful in persons with non-progressive pulmonary
shadowing due to acute (<2-year) sarcoidosis. Additionally,
it advances an evidence-based, biologically plausible
conceptual framework that accounts for this effect.Mortality in tertiary care- (TCS) vs. population
based-settings (PBS)
In a meta-analysis of TCS vs. PBS, CSTwas provided in TCS at
7-fold the rate in PBS (41% vs. 6%). Meanmortality (excluding
one TCS outlier, Johnston, discussed below) differed by an
order ofmagnitude: TCS, 5.1% (range: 4.0e7.6) vs. PBS, 0.5%
(range: 0.0e1.4). Mortality was bimodal (see Fig. 1), with
a broad discontinuity, not a range. After correction for
advanced stage (III, IV), the mortality ratio is 7.5: 1.4
Similarity in the proportion with (prognostically highly
favorable) stage I in TCS vs. PBS (49% vs.59%) indicated that
TCS allocation was not dominated by referral bias, and
Figure 1 Sarcoidosis mortality in population-based (PBS) vs. tertiary-care settings (TCS). RO, Romer32; RE, Reich4; HI, Hillerdal33;
HE, Henke34; JO, Johnston5; SI, Siltzbach35; NE, Neville36; SC, Scadding37; SM, Smellie38; SO, Sones39
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account for the disproportion in provision of CST. That the
900% higher mortality was not wholly attributable to
adverse selection is further evidenced by the strong
correlation between proportion receiving CST in each TCS
and stage-corrected mortality: Spearman’s rank correlation
coefficient (rs) Z 0.68; rs
2 reflecting CST-attributable
mortality risk Z 46%.4
Johnston (JOdsee Fig. 1), reported that the stage
distribution his 159 TCS patients was 81 (51%) stage I and 27
(17%) stage III, nearly identical to the reporting TCS.4 His
conservative indication for CSTdprogressive
shadowingdled to its provision in only 3%; 4 of 5 persons
with residual shadowing exhibited minimal fibrosis; and
sarcoidosis mortality was zero.5
Controlled CST trials
A systematic review showed that disease duration exerted
a dominant influence on outcome: In persons with acute
sarcoidosis and pulmonary shadowing, each of five compe-
tent controlled trials demonstrated a 2e4-fold ratio of
adverse outcomes (including mortality) in CST recipients vs.
controls. (Three trials were excluded due to fatal flaws in
design or execution.) Its effect was neutral in intermediate
duration disease and favorable in chronic progressive cases.6
A Cochrane meta-analysis, which demonstrated no
clear-cut benefit or harm, conflated trials whose subjects
had sarcoidosis of various duration, persons with stage I
disease and trials of inhaled CST.7 Persons with stage I are
ordinarily exempted from treatment due to their high rate
of spontaneous remission and absence of prefibrotic
pulmonary shadowing. Due to its limited efficacy, inhaled
CST is not recommended for treatment of persons with
pulmonary shadowing. These design limitations render this
analysis inapplicable to persons with acute, non-progres-
sive pulmonary shadowing.
The British Thoracic Society study8 circumvented criti-
cisms addressed to earlier controlled trialsdlack of a run-inperiod to eliminate patients whose disease would have
resolved or improved spontaneously short-term, and failure
to treat for a sufficient length of time and at an individu-
ally-tailored dose. The investigators selected newly pre-
senting patients exhibiting pulmonary shadowing and
provided a run-in period of six months to allow for spon-
taneous improvement or resolution. Persons who improved
spontaneously within six months constituted an observed
group (O, nZ 58). Persons whose symptoms did not require
immediate CST were alternately assigned to long-term (L,
n Z 27) group who were treated for 1-year at a dose
sufficient to achieve and sustain maximum radiographic
improvement, or to the selectively treated control group
(S, n Z 27), who were treated (n Z 6) as necessary for
relief of dyspnea or deterioration in pulmonary function.
There was an imbalance in allocation between the L and S
cohorts favoring the former who had a higher mean baseline
DLCO, and half the numberwith stage IV. Themean age in the
L group (40.5) was 7-years beyond the O group (33.2), and 22%
of the combined S and L groups were stage IV at allocation,
indicating that a substantial proportion had chronic sarcoid-
osis. After adjustment for imbalances, small improvements in
dyspneaandpulmonary function favored the L vs. the S group.
It is open to question whether this minor benefit of intensive
CSTwould obtain in persons with acute sarcoidosis exhibiting
non-progressive pulmonary shadowing.9
In summary, the marked outcome advantage observed in
settings in which provision of CST was constrained and in
the control cohorts in CST trials involving acute sarcoidosis
reinforce the conservative ATS/ERS/WASOG10 and UK11
treatment guidelines for intrathoracic sarcoidosis, which
recommend treatment only for those exhibiting progressive
pulmonary shadowing.
Revised conceptual framework
Sarcoidosis may be pathophysiologically defined12 as an
etiologically diverse SGR attributable to inefficient cell
mediated immunity. This conceptual frameworkpredicts and
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multifarious, unexplained, enigmatic features of sarcoid-
osis. Immunological assessment, prediction verification and
clinical corroboration reciprocally validate the conceptual
framework:
Mathew et al. employed an in vitromethodology to assess
the SGR in sarcoidosis.13 Their finding of isolated, attenuated
myeloid dendritic cell function supported and extended
Munro’s earlier observations characterizing the disordered
cellular components of the early (10e18-day) Kveim
response in Kveim-positive persons with sarcoidosis vs.
healthy controls.14 They concurred with Munro’s inference
that “Granuloma formation occurswhen the cellular immune
response fails to eliminate the antigenic stimuli.”.13
The hypothesis that the SGR characterizing sarcoidosis is
an immunological fallback reflecting an inefficient cellular
immune response to an unspecified antigen predicts or
accords with these observations:1) The etiology is elusive15 precisely because it does not
exist. In this conceptual framework, sarcoidosis is
viewed as a syndrome. Tuberculosis,16 neoplasia,17
histoplasmosis,18,19 and beryllium inhalation20 infre-
quently incite a (variously designated) SGR virtually
indistinguishable from sarcoidosis. (The proportion of
SGRs manifested in these etiologically defined cate-
gories approximates the incidence of positive Kveim
responses in otherwise normal individualsd0.7e2%.21).
This concept predicts that other agents22 will become
provisional etiological candidates, awaiting confirma-
tion by multiple concurring observations.
2) Persons with cellular immune deficiencies exhibit
a propensity to develop SGR indistinguishable from
sarcoidosis.23,24
3) An intense immune response (in this setting of impaired
efficiency) signals a favorable outcome25e28;
conversely, its suppression with CST, as noted above, is
harmful. Augmentation of CST with Cyclosporin-A
(which reduces IL-2, a principal cytokine enhancing
granulomatous inflammation) intensifies this adverse
effect.29 Conversely, thalidomide, which augments
dendritic cell activation and T-cell infiltration of gran-
ulomas, ameliorates cutaneous sarcoidosis.30
4) Kveim suspension provides an antigenically nonspecific
challenge (Numerous efforts to develop an in vitro
Kveim test failed to elicit a sensitive and specific T-cell
response.21) that elicits histological features of immune
dysfunction characterizing sarcoidosis. The immune
paradoxdexuberant granulomatous inflammation in
affected organs accompanied by cutaneous anergy-
dare dual manifestations of the same impairment. For
example, a high proportion of healthy young adults
failing to convert their tuberculin test following
repeated BCG immunizations were Kveim-positive.31
This conceptual framework is falsifiable by demon-
strating that it fails to comport materially with experience
or by the simple expedient of ascertaining the etiological
agent of sarcoidosis. This analysis supports treatment
recommendation advocated by Scadding, Hillerdal, John-
ston, Gottlieb, Israel, Hunninghake and Turner-Warwick
among others, and current guidelines. Adherence toconservative indications for intervention will substantially
diminish the number of persons receiving sustained CST and
reduce sarcoidosis mortality to <1%.
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